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is and meningitis were detected. Age-speciﬁc proportions
f those <5 years with suspected disease were 43% (n = 530)
-11 months, 32% (n = 387) 1 year, and 25% (n = 308) 2-4
ears. Of those aged ‘‘5 years, 42% (n = 100) were <15 years
nd 58% (n = 138) were ≥15.7% (95/1385) of blood cultures
rew pathogens; 38% (36/95) pneumococcus and 20% (19/95)
taphylococcus aureus. 80% (76/95) of invasive bacterial dis-
ase occurred <5 years of age. 86% (25/29) of IPD <5 years
f age was associated with pneumonia and there were seven
ases of bacterial meningitis. All cases of IPD ‘‘5 years of
ge were associated with pneumonia and there were two
ases of bacterial meningitis. The estimated incidence of
PD per 100000 person years was 362 (2-11 months), 295
1 year), 56 (2-4 years), 4 (5-14 years) and 9 (≥15 years).
he serotype distribution of 90 IPD episodes since initiation
f pilot surveillance was: serotype 1: (28), 6A: (11), 5: (9),
4: (9), 19A: (3), 4: (3), 23F (2), 6B (2), 7F (2), other (21).
he proportions of IPD covered by different vaccines were:
PCV 20%, 7PCV + 6A 32%, PHiD10CV 63%, PHiD10CV + 6A 76%,
3PCV 79%.
Conclusion: The burden of childhood pneumococcal dis-
ase in rural West Africa is substantial. The relative burden
mong older children and adults is much less. Vaccines of
reater valence than 7PCV will cover substantially greater
roportions of IPD. Ongoing high quality surveillance is criti-
al to document the effectiveness of vaccine introduction
nd to provide data to inform immunization programs in
esource limited settings.
oi:10.1016/j.ijid.2010.02.1548
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Background: Cholera is a diarrhoeal disease caused by
nfection with the bacterium Vibrio Cholerae. It affects
oth children and adults. It has a short incubation period
nd potent enterotoxins resulting in severe dehydration and
eath within a few hours to days if treatment is delayed.
n Africa, Cholera is a major cause of preventable morbidity
nd mortality. With eight different outbreaks in 2009 alone,
holera epidemics have become a recurring public health
hallenge in 7 regions of Tanzania namely Tanga, Kigoma,
g
c
H
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wanza, Singida, Dar Es Salaam, Zanzibar and Mara. Of
ecent, a cholera vaccine trial is being piloted in Zanzibar
ith the aim of reducing the burden of disease. The objec-
ive of the study was to investigate the risk factors for the
ecent cholera outbreak in Zanzibar so as to plan for con-
rol measures which will be applicable to other regions in
anzania
Methods: Unmatched case-control study was carried out
n the West Unguja District of Zanzibar in October 2009.
tool specimen from cases and water samples from the
earby river, taps, boreholes and wells were collected for
aboratory analysis. Data analysis was done using Epi Info.
Results: Factors found to be associated with cholera
nfection included use of water from bore holes OR = 9.1
p = 0.000) and the river OR = 14.9 (p = 0.000), storage of
ater in buckets OR = 15.5 (p = 0.002) and jerry cans OR = 5.5
p = 0.000) and living in a dirty environment (p = 0.000).Boil-
ng of water OR = 0.11(p = 0.002), storage of water in plastic
ottles OR = 0,1(p = 0.017), education (p = 0.000) and wash-
ng of hands after use of toilet (p = 0.000) were found to
e protective. There was no statistically signiﬁcant differ-
nce between those that had vaccination against cholera
nd others (p = 0.74).
Conclusion: Following the conclusions of our epidemio-
ogical studies, a drastic change of strategy was proposed
hich concentrated in community awareness, personal
ygiene and provision of clean and safe water. Vacci-
ation has never been found to be an effective public
ealth intervention in cholera outbreak as shown in this
tudy.
oi:10.1016/j.ijid.2010.02.1549
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Background:Given increased international travel by high-
isk groups (immunocompromised persons and those with
edical comorbidities), there is need for better characteri-
ation of these travelers and their travel risks. Our objective
as to describe the demographics, travel plans and vacci-
ation requirements of immunocompromised travelers and
hose with medical comorbidities.
Methods: Boston Area Travel Medicine Network (BATMN)
s a research collaboration of ﬁve travel clinics in the
reater Boston area that sees ∼7,500 travelers per year. We
ompared immunocompromised travelers (e.g., those with
IV/AIDS, malignancy, etc) to those with underlying medi-
al conditions (e.g., cardiovascular and pulmonary disease),
